Cargando…
Updates in therapeutic drug monitoring in inflammatory bowel disease
Biologics and immunomodulators (IMM) are generally considered the most effective therapies for the treatment of ulcerative colitis and Crohn’s disease. However, despite the efficacy of these therapies, many patients either have a primary lack of response or a secondary loss of response to these medi...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9185221/ https://www.ncbi.nlm.nih.gov/pubmed/35800180 http://dx.doi.org/10.3748/wjg.v28.i21.2282 |
_version_ | 1784724670479597568 |
---|---|
author | Lodhia, Nilesh Rao, Shanti |
author_facet | Lodhia, Nilesh Rao, Shanti |
author_sort | Lodhia, Nilesh |
collection | PubMed |
description | Biologics and immunomodulators (IMM) are generally considered the most effective therapies for the treatment of ulcerative colitis and Crohn’s disease. However, despite the efficacy of these therapies, many patients either have a primary lack of response or a secondary loss of response to these medications. Therapeutic drug monitoring (TDM) is a systematic approach to managing such patients. In this review, we summarize the latest data on TDM, including reactive and proactive TDM, in patients with inflammatory bowel disease on biologics and/or IMM. |
format | Online Article Text |
id | pubmed-9185221 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-91852212022-07-06 Updates in therapeutic drug monitoring in inflammatory bowel disease Lodhia, Nilesh Rao, Shanti World J Gastroenterol Minireviews Biologics and immunomodulators (IMM) are generally considered the most effective therapies for the treatment of ulcerative colitis and Crohn’s disease. However, despite the efficacy of these therapies, many patients either have a primary lack of response or a secondary loss of response to these medications. Therapeutic drug monitoring (TDM) is a systematic approach to managing such patients. In this review, we summarize the latest data on TDM, including reactive and proactive TDM, in patients with inflammatory bowel disease on biologics and/or IMM. Baishideng Publishing Group Inc 2022-06-07 2022-06-07 /pmc/articles/PMC9185221/ /pubmed/35800180 http://dx.doi.org/10.3748/wjg.v28.i21.2282 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
spellingShingle | Minireviews Lodhia, Nilesh Rao, Shanti Updates in therapeutic drug monitoring in inflammatory bowel disease |
title | Updates in therapeutic drug monitoring in inflammatory bowel disease |
title_full | Updates in therapeutic drug monitoring in inflammatory bowel disease |
title_fullStr | Updates in therapeutic drug monitoring in inflammatory bowel disease |
title_full_unstemmed | Updates in therapeutic drug monitoring in inflammatory bowel disease |
title_short | Updates in therapeutic drug monitoring in inflammatory bowel disease |
title_sort | updates in therapeutic drug monitoring in inflammatory bowel disease |
topic | Minireviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9185221/ https://www.ncbi.nlm.nih.gov/pubmed/35800180 http://dx.doi.org/10.3748/wjg.v28.i21.2282 |
work_keys_str_mv | AT lodhianilesh updatesintherapeuticdrugmonitoringininflammatoryboweldisease AT raoshanti updatesintherapeuticdrugmonitoringininflammatoryboweldisease |